title: A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice.
abstract: A novel strain of Lactobacillus johnsonii No. 1088 was isolated from the gastric juice of a healthy Japanese male volunteer, and characterized for its effectiveness in the stomach environment. Lactobacillus johnsonii No. 1088 was found to have the strongest acid resistance among several lactobacilli examined (>10% of cells survived at pH 1.0 after 2 h), and such a high acid resistance property was a specific characteristic of this strain of L. johnsonii. When cultured with various virulent bacteria, L. johnsonii No. 1088 inhibited the growth of Helicobacter pylori, Escherichia coli O-157, Salmonella Typhimurium, and Clostridium difficile, in which case its effectiveness was more potent than that of a type strain of L. johnsonii, JCM2012. In addition to its effect in vitro, L. johnsonii No. 1088 inhibited the growth of H. pylori in human intestinal microbiota-associated mice in both its live and lyophilized forms. Moreover, L. johnsonii No. 1088 suppressed gastric acid secretion in mice via decreasing the number of gastrin-positive cells in the stomach. These results taken together suggest that L. johnsonii No. 1088 is a unique lactobacillus having properties beneficial for supporting H. pylori eradication by triple therapy including the use of a proton pump inhibitor (PPI) and also for prophylaxis of gastroesophageal reflux disease possibly caused after H. pylori eradication as a side effect of PPI.
authors.affiliation: Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa, 259-1103, Japan.|Snowden Co., Ltd., Chiyoda-ku, Tokyo, 101-0032, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Aiba
authors.affiliation: Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa, 259-1103, Japan.|Snowden Co., Ltd., Chiyoda-ku, Tokyo, 101-0032, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nakano
authors.affiliation: Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa, 259-1103, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Koga
authors.affiliation: Snowden Co., Ltd., Chiyoda-ku, Tokyo, 101-0032, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Takahashi
authors.affiliation: Snowden Co., Ltd., Chiyoda-ku, Tokyo, 101-0032, Japan.
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Komatsu
mesh_terms: D000818:Animals; D000898:Antibiosis; D004195:Disease Models, Animal; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood / Q000378:metabolism*; D000069196:Gastrointestinal Microbiome; D016481:Helicobacter Infections / Q000378:metabolism / Q000382:microbiology; D016480:Helicobacter pylori / Q000502:physiology*; D006801:Humans; D007778:Lactobacillus / Q000302:isolation & purification / Q000502:physiology*; D051379:Mice; D054328:Proton Pump Inhibitors / Q000494:pharmacology
chemical_list: D005755:Gastrins; D054328:Proton Pump Inhibitors
keywords: Gastroesophageal reflux disease; Helicobacter pylori; Lactobacillus johnsonii; lactic acid bacteria; probiotics